Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal propranolol for chronic central serous chorioretinopathy
IRCT20251207068237N1Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol in Central Serous Chorioretinopathy (CSCR), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Central macular thickness, Visual acuity and 1 more. Started Dec 2025; status: completed.
02
Drugs
propranolol
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on IRCT20251207068237N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251207068237N1.